Market News

• How to Tell If a GLP-1 Price Comparison Is Trustworthy

  A dated method for reading any GLP-1 provider comparison, including ours: who wrote it, when each price was read, and who is paid for the placement.

  Sep 19, 2026

• Novo Signs $1.4B Oral Macrocycle Peptide Deal With Orbis

  Novo Nordisk will pay up to $1.4 billion for Orbis Medicines' AI-designed oral macrocycle peptides, aimed at targets now reachable only by injection.

  Sep 17, 2026

• BioLife Wins Oral Peptide Delivery Patent as GLP-1 Pills Race On

  BioLife's U.S. Patent 12,667,605 B2 covers an effervescent tablet built to carry peptides like semaglutide past the stomach, where absorption fails.

  Sep 10, 2026

• Wegovy Pill vs Foundayo: What the Weekly Prescription Data Shows

  Fierce Pharma's weekly tracker now follows the oral GLP-1 race edition by edition. As of Sept 11, 2026: Wegovy pill ~183,000 scripts, Foundayo ~47,500.

  Sep 10, 2026

• Peptide-Drug Conjugate TS-104 Clears FDA IND With $62.5M Series A

  TwoStep Therapeutics said the FDA cleared its IND for TS-104, a peptide-drug conjugate that targets five tumor integrins, alongside a $62.5 million Series A.

  Sep 9, 2026

• Medicare GLP-1 Bridge program: $50 Wegovy, Zepbound

  Medicare GLP-1 Bridge program: qualifying Part D beneficiaries get Wegovy, Zepbound (KwikPen), or Foundayo for $50 a month. What 2026 open enrollment means.

  Sep 2, 2026

• Peptide Synthesis Market to Reach $7 Billion by 2035 on GLP-1 Demand

  A Roots Analysis report projects the peptide synthesis market will grow from $4.4 billion in 2026 to $7 billion by 2035 as GLP-1 demand strains capacity.

  Aug 31, 2026

• Samsung Biologics Launches Tender Offer for Peptide CDMO PolyPeptide

  Samsung Biologics' Swiss arm opened a CHF 1.46 billion tender offer for peptide CDMO PolyPeptide at a 40% premium, a consolidation in peptide manufacturing.

  Aug 30, 2026

• Why Won't My Employer Cover GLP-1? 2026 Coverage Gap

  Employer GLP-1 coverage is shrinking: why plans drop weight-loss drugs, what GLP-1 costs in 2026 without insurance, and semaglutide prices explained.

  Aug 30, 2026

• Retatrutide Liver Failure: Fake Peptides Symptoms & Safety

  Retatrutide liver failure cases in Victoria: seven hospitalized after unapproved peptides. See fake peptides symptoms and a safety checklist.

  Aug 29, 2026

• GLP-1 Cost in 2026: $249/mo Telehealth Plans Compared

  How much does GLP-1 cost in 2026? Compare $249/mo DirectMeds plans, brand-name prices, and the cheapest GLP-1 online options in one guide.

  Aug 29, 2026

• Peptide Manufacturing Ramps Up: Vector Science Begins Production

  Vector Science's LyoGenesis facility began producing pharma-grade peptides Aug 24 — 55,000 vials monthly now, up to 800,000 planned as compounding demand grows.

  Aug 25, 2026

• New Obesity Drugs 2026: The Muscle-Saving UCN2 Peptide

  Genentech's $2.3B Hanmi deal for HM17321 — a UCN2 peptide that burns fat while preserving muscle — signals the next wave of obesity drugs beyond GLP-1.

  Aug 24, 2026

• Urocortin-2 Peptide: Genentech's $2.3B Muscle-Sparing Obesity Bet

  Genentech paid Hanmi $190M upfront for HM17321, a urocortin-2 peptide that burns fat while sparing muscle - the GLP-1 class's biggest weakness.

  Aug 24, 2026

• Counterfeit Retatrutide: 7th Liver Toxicity Case Prompts Batch Testing

  Australia's counterfeit retatrutide cluster grows to seven liver toxicity cases, with doctors testing suspect batches and the TGA warning again.

  Aug 23, 2026

• Hims & Hers Compounded Peptides: Year-End Launch Plans

  Hims & Hers plans compounded peptides NAD+, sermorelin, and glutathione by year-end, with six more awaiting FDA rulemaking. Analysts see a $2.2-3.3B market.

  Aug 14, 2026

• Huberman Lab Drops 3-Hour Peptides Masterclass With Dr. Abud Bakri

  Huberman Lab aired a three-hour peptide deep dive with Dr. Abud Bakri on BPC-157, GHK-Cu, epitalon, GLP-1s, and the evidence gap driving todays peptide boom.

  Jun 1, 2026

• CordenPharma Acquires AmbioPharm in Major Peptide CDMO Expansion

  CordenPharma acquires AmbioPharm, adding two peptide API facilities (U.S. and China) with 400 employees, as peptide manufacturing becomes a strategic priority.

  May 26, 2026

• Fox News Examines 'Wild West' Peptide Craze as FDA Faces Pressure

  Dr. Alex Tatem tells Fox News the peptide market boom poses risks and opportunities as the FDA weighs rule changes on several peptides this summer.

  May 21, 2026

• Parabilis Medicines Files IPO After $2.3B Regeneron Peptide Alliance

  Cambridge peptide biotech Parabilis debuts on Nasdaq after landing a $2.3 billion Regeneron partnership and posting 74% tumor response in Phase 1/2 trials.

  May 20, 2026

• Vector Sciences Inks Peptide Manufacturing Deal for $80.8B Market

  Vector Sciences and MPP Group partner to produce 22 shelf-stable peptides in a cGMP facility — the first major deal since the April FDA reclassification.

  May 19, 2026

• Media Surge: Forbes, Men's Health Call for Peptide Oversight

  Forbes warns peptides went mainstream without safeguards, as Men's Health reviews 100+ studies and Men's Fitness highlights BPC-157 research.

  May 18, 2026

• Men in Their 40s Driving the Peptide Therapy Boom, New Reports Show

  Men's Health and other outlets document surging interest from midlife men as the peptide boom broadens beyond biohackers, outrunning regulatory guardrails.

  May 14, 2026

• Peptide Revolution Reaches The Times, Oprah Daily, Globe and Mail

  The Times examines the injectable peptide industry — joining Oprah Daily, the Globe and Mail, and Glossy in a global mainstream coverage wave.

  May 12, 2026

• Media Wave Converges on Unapproved Peptide Injections — WSJ, SciAm, FT

  WSJ, Scientific American, FT, and The Conversation all covered unapproved peptide injections in one week — a media turning point for the peptide debate.

  May 7, 2026

• The Peptide Problem: Major Media Outlets Question Hype vs. Evidence

  Major media outlets question whether demand for peptide therapies has outpaced the science behind them, ahead of a critical FDA review in July.

  May 6, 2026

• Post-April 15, Where You Live Matters More Than You Think

  Federal peptide reclassification sets the floor; state pharmacy boards set the ceiling. Ten states plus DC keep restrictive regimes that add real friction.

  Apr 29, 2026

• The Telehealth Brands Most Likely to Pivot Into Peptides After PCAC

  GLP-1 telehealth providers have the prescribers, compounding ties, and DTC marketing muscle to dominate peptides after PCAC. Who's positioning, and the impact.

  Apr 28, 2026

• Compounding Pharmacies Quietly Positioning Ahead of July PCAC Meeting

  The 90 days between the April 15 peptide reclassification and the July PCAC meeting are when the supply chain repositions. What's happening, and why it matters.

  Apr 24, 2026